Descriptive study of the general practitioners’ perception of direct oral anticoagulants and the risk of genital bleeding in women of childbearing age
- 1 July 2020
- journal article
- research article
- Published by Elsevier in JMV-Journal de Médecine Vasculaire
- Vol. 45 (4) , 198-209
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017Research and Practice in Thrombosis and Haemostasis, 2019
- Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE studyBJOG: An International Journal of Obstetrics & Gynaecology, 2018
- Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolismVascular Pharmacology, 2017
- Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolismVascular Pharmacology, 2016
- Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trialsInternational Journal of Cardiology, 2016
- Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useBlood, 2016
- Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonistsThrombosis Research, 2015
- Heavy menstrual bleeding on rivaroxabanBritish Journal of Haematology, 2015
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012